Evidence map›Paper›PMID 40585031›Full record

ArticleMaterials today. Bio2025

Bone marrow-targeted thrombopoietin delivery via engineered platelet-derived vesicle-loaded dissolving microneedles for treating ionizing radiation-induced injury.

Zhenchao Ma, Yuntao Li, Jiawei Zhu, Sheng Qiu, Yingrong Chen, Hengbin Cao, Shuixin Yang, Xueli Jia, Lixia Huo, Qian Shi and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zhenchao MaAffiliated Huzhou Hospital, Zhejiang University School of Medicine, Huzhou Central Hospital, Huzhou, 313000, Zhejiang, China.
Yuntao LiAffiliated Huzhou Hospital, Zhejiang University School of Medicine, Huzhou Central Hospital, Huzhou, 313000, Zhejiang, China.
Jiawei ZhuWenzhou Medical University, School of Pharmacy, Wenzhou, 325035, Zhejiang, China.
Sheng QiuAffiliated Huzhou Hospital, Zhejiang University School of Medicine, Huzhou Central Hospital, Huzhou, 313000, Zhejiang, China.
Yingrong ChenAffiliated Huzhou Hospital, Zhejiang University School of Medicine, Huzhou Central Hospital, Huzhou, 313000, Zhejiang, China.
Hengbin CaoAffiliated Huzhou Hospital, Zhejiang University School of Medicine, Huzhou Central Hospital, Huzhou, 313000, Zhejiang, China.
Shuixin YangAffiliated Huzhou Hospital, Zhejiang University School of Medicine, Huzhou Central Hospital, Huzhou, 313000, Zhejiang, China.
Xueli JiaDepartment of Pharmaceutical Science, School of Pharmacy, Naval Medical University, 800 Xiangyin Road, Shanghai, 200433, China.
Lixia HuoSchool of Medicine, Huzhou University, Huzhou 313000, Zhejiang, China.
Qian ShiSchool of Medicine, Huzhou University, Huzhou 313000, Zhejiang, China.
Shunwen HanAffiliated Huzhou Hospital, Zhejiang University School of Medicine, Huzhou Central Hospital, Huzhou, 313000, Zhejiang, China.
Hao ChangHangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang, China.
Xiang YuAffiliated Huzhou Hospital, Zhejiang University School of Medicine, Huzhou Central Hospital, Huzhou, 313000, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exposure to a nuclear accident or a radiological attack may cause serious death events due to hematopoietic acute radiation syndrome (H-ARS). While thrombopoietin (TPO) shows promise in mitigating myelosuppression, its clinical use is restricted due to high doses, strict schedules, and systemic toxicity from conventional administration. This study developed a dissolving microneedle patch loaded with engineered activated platelet-derived vesicles encapsulating TPO (TLEVs@MN) for targeted treatment of H-ARS. Activated platelet-derived vesicles were isolated via ultracentrifugation and then modified with glutathione. Glutathione-based anti-ROS modification effectively protected vesicles from radiation-induced oxidative damage, enhancing their stability and targeting efficiency. Using mild sonication, TPO was efficiently encapsulated into engineered vesicles without compromising membrane protein integrity. Further loading into dissolving MNs facilitated minimally invasive transdermal delivery while ensuring long-term vesicle stability during storage. TLEVs@MNs effectively activated the JAK2/STAT3 pathway, restoring mitochondrial function in hematopoietic stem cells. Pharmacokinetic and biodistribution analyses demonstrated that administration of TPO using TLEVs@MNs achieved the precise TPO delivery to bone marrow hematopoietic stem and progenitor cells, significantly improving survival rates and hematopoietic recovery in irradiated animal models. These findings highlighted TLEVs@MN patch as a promosing and robust TPO delivery platform for managing IR-induced hematopoietic injury.

Indexed as

Activated platelet-derived vesiclesHematopoietic stem cellsIonizing radiationMicroneedleMitochondriaThrombopoietin

Identifiers

PMID40585031
PMCPMC12206129

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.